PSTV Plus Therapeutics Inc Operating Profitability

Asset volatility for Plus Therapeutics, Inc. (PSTV) is driven by the development of radiotherapy to combat breast and brain tumors. The operating margin curve on the GURU.Markets platform chart shows that the current metric is -364.40. While insurance payments for high-tech treatment provide stability, the lack of recurring revenue due to early-stage drug trials creates typical biotech risks.
Plus Therapeutics Inc - analytical breakdowns and key metrics (PSTV)
- stock quotes and analyst forecast:
- market capitalization data:
- company book value details:
- debt and liquidity data:
Total Debt to Capital Plus Therapeutics, Inc.|PSTV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Plus Therapeutics Inc|PSTV - Company Cumulative Debt|Debt to Book Capitalization Ratio Cytori Therapeutics|PSTV - Company Long-Term Loans and Borrowings|Company Short-Term Debts Plus Therapeutics|Quick Liquidity plustherapeutics.com
- earnings and market ratios statistics:
PSTV - Profit After Tax|Projected Future Earnings Plus Therapeutics, Inc.|PSTV - Market Cap to Earnings|Projected Price to Earnings Cytori Therapeutics|PSTV - PEG Multiple|Enterprise Value to EBITDA Ratio Plus Therapeutics|PSTV - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Plus Therapeutics|PSTV - Net earnings per share for the last four quarters|Quarterly EPS earnings growth plustherapeutics.com|PSTV - Net earnings per share growth this year|Net earnings per share growth forecast for next year Plus Therapeutics, Inc.
- sales and revenue indicators:
- margin level details:
Fundamental company analysis:PSTV, Plus Therapeutics Inc

Investors evaluate operational efficiency by analyzing the share of operating profit relative to total EBITDA. For Plus Therapeutics, Inc. (PSTV), whose radiopharmaceuticals are currently in clinical trials without a stable cash flow, the operating profit margin reflects high project development costs and a lack of self-sustaining cash.